Sanofi boosts its venture arm with a $625 million commitment

Sanofi has announced a new commitment of $625 million to Sanofi Ventures, its corporate venture capital division, in a multi year allocation aimed at accelerating investments in biotech and digital health innovation. This infusion expands the fund’s assets under management to more than $1.4 billion.

The capital will support emerging companies working in Sanofi’s strategic focus areas including immunology, rare diseases, neurology and vaccines. The company has also signalled an interest in new domains such as ophthalmology, neuropsychiatry and pain biology.

Since its founding in 2012, Sanofi Ventures has invested more than $800 million across over 70 companies. Its structure is evergreen, meaning that returns from exits are reinvested to fuel future deals and maintain long term impact.

Sanofi’s leadership describes this as a strategic move to ensure it remains at the forefront of scientific innovation. At a time when early stage biotech funding is tightening, the company believes the venture arm can play a pivotal role by supporting high risk but high potential science.